3P-MACE, 3-point major cardiovascular events

5P-MACE, 5-point major cardiovascular events

ACR, albumin-creatinine ratio

ADM, adrenomedulin

ANGPTL2, angiopoietin like 2

ANGPTL4, angiopoietin like 4

ATE, average treatment effect

BIW, twice weekly

BMI, body mass index

CI, confidence interval

CKD, chronic kidney disease

CKD-EPIcr, Chronic Kidney Disease Epidemiology Collaboration creatinine

CV, cardiovascular

CVD, cardiovascular disease

DBP, diastolic blood pressure

DCCT, Diabetes Control and Complications Trial

DIO, diet-induced obesity

DKD, diabetic kidney disease

DPP-4i, dipeptidyl peptidase 4 inhibitor

eGFR, estimated glomerular filtration rate

EMA, European Medicines Agency

f/u, follow-up

GCGR, glucagon receptor

GLP-1R, glucagon-like peptide-1 receptor

GLP-1RA, glucagon-like peptide-1 receptor agonist

HbA1c, glycated hemoglobin

HCP, healthcare professional

HF, heart failure

HHF, hospitalization for heart failure

HR, hazard ratio

KCCQ-TSS, Kansas City Cardiomyopathy Questionnaire Total Symptom Score

L-FABP, liver-type fatty acid-binding protein

MACE, major adverse cardiovascular events

MASH, metabolic dysfunction-associated steatohepatitis

MI, myocardial infarction

MRI-PDFF, magnetic resonance imaging derived proton density fat fraction

NAS, Non-alcoholic Fatty Liver Disease Activity Score

NASH, non-alcoholic steatohepatitis

PY, person-year

QoL, quality-of-life

QW, once weekly

RCT, randomized controlled trial

SBP, systolic blood pressure

SC, subcutaneous

SD, standard deviation

SGLT2i, sodium-glucose cotransporter 2 inhibitor

SU, sulfonylurea

T1D, type 1 diabetes

T2D, type 2 diabetes

UKPDS, United Kingdom Prospective Diabetes Study

US, United States

VEGF, vascular endothelial growth factor